ClinicalTrials.gg
RecruitingNCT05953779Updated Jul 20, 2023

Personalized Need-focused Single Session Intervention

An interventional study of Clinician-administered Need-focused Single Session Intervention in Depression and/or Anxiety in the Mild-to-moderate Range, sponsored by Bar-Ilan University, Israel. Recruiting at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-20.

Sponsored by Bar-Ilan University, Israel · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2024, 2 years 3 months ago, but the record still lists the study as recruiting.
  • Started Jan 2023; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 3,715 studies in Depression with a site in United States — 579 open to participants now, 716 under way, 29 of them phase 3. Depression · United States.

Planned enrollment
686th of 3,322
240 · median 72
Started
2023
with 224 others
No phase
2,221 of 3,715
386 open now
Primary completion
2024-07
later than 14 of 714 live
Registered
2,984th of 3,715
by date

Among the 3,715 studies in Depression with a site in United States, this one is the 686th largest by planned enrollment of the 3,322 interventional ones that give a count, is one of 225 that started in 2023, is one of 2,221 with no phase, reaches primary completion later than 14 of the 714 other live ones, and was the 2,984th registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

579 of the 3,715 studies in Depression with a site in United States are open now. Recruiting first, the newest first:

574 more — sign in →

All 579 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,715 studies in Depression with a site in United States, or all of them as a file.
02

Study summary

This is a two-site randomized controlled trial, with two goals. First, the investigators aim to demonstrate that single-session interventions for mild-to-moderate anxiety and depression can generate statistically significant symptom change as a main effect across control and experimental (i.e. personalized) conditions. Second, the investigators hope to establish the additional incremental efficacy of personalization via person-specific intensive longitudinal data collection and analysis.

Read the detailed description

This is a two-site randomized controlled trial, with two goals. First, the investigators aim to demonstrate that single-session interventions for mild-to-moderate anxiety and depression can generate statistically significant symptom change as a main effect across control and experimental (i.e. personalized) conditions. Second, the investigators hope to establish the additional incremental efficacy of personalization via person-specific intensive longitudinal data collection and analysis.

All single-session interventions will be 90-minutes in length. At the conclusion of the intervention session, participants will receive suggestions for daily homework practice to complete and a flash drive with a copy of their session audio to review at their discretion. Participants will also meet with the therapist for a 10-minute remote check-in two weeks following the single session.

All interventions include standard psychoeducational components. Participants randomized to the personalization arm of the study will be given an intervention matched to their most pressing psychosocial need. Participants randomized to the control condition will receive a standard intervention (at the UCB site) or a randomly selected one (at the BIU site). Both the standard intervention and the specific ones were designed to be broadly efficacious for depression and anxiety symptomatology.

The psychosocial needs which serve as the focus of the interventions are derived from motivation and affect regulation models and include emotional stability, predictability, acceptance, competence, self-esteem, autonomy, and pleasure. The primary unmet need for each individual will be determined by a conditional entropy algorithm. Simply, the presence versus absence of subjective distress will be measured eight times per day for 30 days. Concurrently, the presence versus absence of need frustration will also be measured eight times per day for 30 days. Utilizing a k-fold cross-validated estimation, conditional entropy will be used to determine the need that best reduces the uncertainty in subjective distress (that is, best explains its presentation probabilistically).

03

Conditions studied

  • Depression and/or Anxiety in the Mild-to-moderate Range

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criterion.

* a score of 5 or above on the Hamilton Rating Scale for Depression (HRSD).

Exclusion Criteria based on Diagnostic Interview for Anxiety, Mood, and Obsessive-Compulsive and Related Disorders (DIAMOND).

  • Psychotic Disorders (hallucinations or delusions)
  • Past or current mania, current hypo-mania.
  • Anorexia Disorder
  • Current Obsessive-Compulsive and related Disorders rated as moderate and above.
  • Alcohol or drug abuse rated as moderate and above.
  • Panic Disorder rated as moderate and above.
  • Agoraphobia rated as moderate and above.
  • Premenstrual dysphoric disorder rated as moderate and above.
  • Current Post-Traumatic Stress Disorder rated as moderate and above.
  • binge eating rated as moderate and above.
  • Phobia rated as severe and above.
  • Somatic symptom disorder rated as severe and above.
  • Illness Anxiety Disorder rated as severe and above.
  • MDD rated as severe and above.
  • GAD rated as severe and above.
  • Social Anxiety rated as severe and above.
  • Separation anxiety rated as severe and above.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    Personalized Intervention

    The intervention approach taken in this RCT is focused on unmet psychological needs (predictability, belonging, competence, self-worth, autonomy, and playfulness). For each need, a specific 90-minute intervention has been developed. The primary unmet need for each individual will be determined by a conditional entropy algorithm. Simply, the presence versus absence of subjective distress will be measured eight times per day for 30 days. Concurrently, the presence versus absence of need frustration will also be measured eight times per day for 30 days. Utilizing a k-fold cross-validated estimation, conditional entropy will be used to determine the need that best reduces the uncertainty in subjective distress (that is, best explains its presentation probabilistically). At both sites, the experimental condition will consist of an algorithmically-chosen intervention. The choice will be made based on data collected during thirty days of ecological momentary assessment.

    Behavioral: Clinician-administered Need-focused Single Session Intervention

  • Active comparator
    Non-personalized Intervention

    The intervention approach taken in this RCT is focused on unmet psychological needs (predictability, belonging, competence, self-worth, autonomy, and playfulness). For each need, a specific 90-minute intervention has been developed. At the BIU site, the active control condition will consist of an intervention chosen randomly (out of the six mentioned above). At the UCB site, the active control condition will consist of a standard intervention addressing emotion regulation difficulties.

    Behavioral: Clinician-administered Need-focused Single Session Intervention

Interventions

  • BehavioralClinician-administered Need-focused Single Session Intervention

    All single-session interventions will be 90-minutes in length. At the conclusion of the intervention session, participants will receive suggestions for daily homework practice to complete and a flash drive with a copy of their session audio to review at their discretion. They will also meet with the therapist for a 10-minute remote check-in two weeks following the single session. All interventions include standard psychoeducational components. Both the standard intervention and the specific ones were designed to be broadly efficacious for depression and anxiety symptomatology. The psychosocial needs which serve as the focus of the interventions are derived from motivation and affect regulation models.

06

What researchers measure

Primary outcomes

  1. Hamilton-Depression Rating Scale

    (Range 0-52, higher scores denote greater depression)

    Time frame: Change between pre-intervention and 1 month post-intervention

  2. Montgomery-Asberg Depression Rating Scale

    (Range 0-60, higher scores denote greater depression)

    Time frame: Change between pre-intervention and 1 month post-intervention

  3. Hamilton-Anxiety Rating Scale

    (Range 0-56, higher scores denote greater anxiety); will be used in lieu of Hamilton-Depression ratings for individuals whose Hamilton-Anxiety scores are higher than their Hamilton-Depression scores.

    Time frame: Change between pre-intervention and 1 month post-intervention

Secondary outcomes

  1. PHQ-8

    (Range 0-24, higher scores denote greater depression)

    Time frame: Immediately prior to intervention, and again at 1 and 3 months post-intervention

  2. GAD-7

    (Range 0-21, higher scores denote greater anxiety)

    Time frame: Immediately prior to intervention, and again at 1 and 3 months post-intervention

  3. DASS

    (Range 0-63, higher scores denote greater depression, anxiety, and stress)

    Time frame: Immediately prior to intervention, and again at 1 and 3 months post-intervention

Other outcomes

  1. PANAS

    Positive and negative affect schedule (20 items)

    Time frame: Up to six weeks prior to intervention, and again at 1 and 3 months post-intervention

  2. ERQ

    Emotion Regulation Questionnaire

    Time frame: Up to six weeks prior to intervention, and again at 1 and 3 months post-intervention

  3. DERS-18

    Difficulties in Emotion Regulation

    Time frame: Up to six weeks prior to intervention, and again at 1 and 3 months post-intervention

  4. PSQI

    Pittsburgh Sleep Quality Index

    Time frame: Up to six weeks prior to intervention, and again at 1 and 3 months post-intervention

  5. IIP-32

    Inventory of Interpersonal Problems

    Time frame: Up to six weeks prior to intervention, and again at 1 and 3 months post-intervention

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — De-identified data will be made available through the osf.io platform or similar platforms.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Jul 2024, 18 months after the start.

Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 18 months is below that.

Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2023
First posted
Jul 20, 2023
StartActual
Jan 8, 2023
Primary completionEst.
Jul 31, 2024
CompletionEst.
Sep 30, 2024
Last update
Jul 20, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05953779
Lead sponsor
Bar-Ilan University, Israel
Collaborators
University of California, Berkeley, United States - Israel Binational Science Foundation
Responsible party
Prof. Eshkol Rafaeli (Professor, Bar-Ilan University, Israel) — Principal investigator
First posted
Jul 20, 2023
Start date
Jan 8, 2023
Primary completion
Jul 31, 2024 (estimated)
Completion
Sep 30, 2024 (estimated)
Last update
Jul 20, 2023

Study contacts

Eshkol Rafaeli, PhD
Contact
eshkol.rafaeli@gmail.com
+972-3-7384660
Gal Lazarus, PhD
Contact
gal.lazarus@gmail.com

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion